What Researchers Did
Researchers reviewed the current evidence regarding hyperbaric oxygen therapy (HBOT) in both experimental and clinical stroke settings.
What They Found
Numerous basic and clinical studies since the 1960s have indicated beneficial effects of HBOT on neurological outcomes after stroke, illustrating mechanisms such as improved cerebral oxygenation, anti-inflammation, and neural regeneration. However, the evidence for HBOT in human stroke is not yet sufficient due to a lack of randomized double-blind controlled clinical studies. Furthermore, there are currently no uniform criteria for the optimal dose and duration of HBOT sessions.
What This Means for Canadian Patients
For Canadian patients, hyperbaric oxygen therapy is not currently a standard, evidence-based treatment for stroke due to insufficient high-quality clinical studies. Patients should discuss all treatment options with their healthcare providers, as further research is needed to establish clear guidelines for HBOT in stroke.
Canadian Relevance
This study has no direct Canadian connection, as it did not involve Canadian researchers, institutions, or patients.
Study Limitations
The primary limitation highlighted is the insufficient number of randomized double-blind controlled clinical studies on HBOT in human stroke, leading to a lack of uniform treatment criteria.